当前位置: 首页 > 期刊 > 《中国现代医生》 > 2016年第6期
编号:12754776
盐酸帕洛诺司琼预防肿瘤化疗引起的恶心呕吐的疗效观察(1)

     [摘要] 目的 评价盐酸帕洛诺司琼注射液预防肿瘤化疗引起的恶心呕吐的疗效。 方法 将我院2013年1月~2014年12月收治的肺癌和乳腺癌患者40例分为A组和B组,各20例,A组采用盐酸帕洛诺司琼首日给药0.25 mg,B组采用盐酸帕洛诺司琼在第1、3、5天给予0.25 mg/d。观察两组患者的疗效及不良反应情况。 结果 A组和B组在急性期恶心完全缓解率差异无统计学意义(55.0% vs 60.0%,P>0.05),但在延迟期B组恶心完全缓解率明显高于A组(67.5% vs 52.5%,P<0.05)。A组和B组在急性期呕吐的完全缓解率差异无统计学意义(82.5% vs 80.0%, P>0.05),但在延迟期B组呕吐完全缓解率明显高于A组(87.5% vs 70.0%,P<0.05)。两组不良反应总发生率分别为7.5%、10.0%,差异有统计学意义(P<0.05)。 结论 多次重复给予盐酸帕洛诺司琼较单剂量盐酸帕洛诺司琼,可以提高化疗患者的延迟期恶心呕吐完全缓解率,且两者不良反应相似。

    [关键词] 盐酸帕洛诺司琼;化学治疗;恶心;呕吐

    [中图分类号] R730.5 [文献标识码] B [文章编号] 1673-9701(2016)06-0066-03

    Clinical observation of palonosetron hydrochloride injection in prevention of nausea and vomiting caused by cancer chemotherapy

    YU Xiaoyun

    Department of Internal Medicine of Oncology, Pulandian Center Hospital in Liaoning Province, Pulandian 116200, China

    [Abstract] Objective To evaluate the curative effect of palonosetron hydrochloride injection in prevention of nausea and vomiting caused by cancer chemotherapy. Methods A total of 40 patients with lung cancer and breast cancer in our hospital from January 2013 to December 2014 were divided into group A and group B, 20 cases in each group, patients in group A were treated with palonosetron hydrochloride 0.25 mg on the first day, patients in group B were treated with palonosetron hydrochloride 0.25 mg/d on the first day, the third day and the fifth day. The curative effect and adverse reaction of the two groups were observed. Results There was no significant difference about the overall remission rates of nausea in the acute phase between group A and group B(55.0% vs 60.0%,P>0.05), but the overall remission rates of nausea in the delay period in group B was significantly higher than in group A(67.5% vs 52.5%). There was no significant difference about the overall remission rates of vomiting in the acute phase between group A and group B (82.5% vs 80.0%,P>0.05),but the overall remission rates of vomiting in the delay period in group B was significantly higher than in group A(87.5% vs 70.0%,P>0.05). The total incidence of adverse reaction in the two groups were respectively 7.5% and 10.0% the difference was statistically significant (P<0.05). Conclusion Compared with single dose, palonosetron hydrochloride repeatedly given can improve the overall remission rates of nausea and vomiting in the delay period in chemotherapy patients, and the incidence of adverse reaction is similar.

    [Key words] Palonosetron hydrochloride; Chemotherapy; Nausea; Vomiting(于小云)
1 2 3下一页
    濞e洠鍓濇导鍛閸涱剛杩旈柛娆忓€介埀顒€鍠涚槐婵囩▔瀹ュ棛鈧垶骞嬮幇顏呭床濞达絾娲戠粻锝咁嚈妤︽鍞撮柕鍡曠劍鐢綊鎳¢幇顓炵仐闁圭ǹ娲ょ槐鈺呭Υ閸屾稒鐎紒鏃傚Х婢ф寮堕崘銊ф剑濞存粌楠哥敮顐︽媼濡炲墽绋婇柡澶婂暕濮瑰鏁嶅畝鍐仧闁诡喓鍔忛缁樼▔閻戞﹩鍔冮柡鍌氭矗缁楀鈧绮忛~锕傚绩鐠鸿櫣绉垮〒姘☉閵囧洨鈧娉涢崢銈囨嫻瑜版帗顫夐悹鍥︾串缁辨繄鎷犻悜钘変粡濞寸姾鍩栭崹銊╂偨娴e啰妯堥梺顐f皑閻擄繝骞嬮幋婊勭拨闁挎稑鏈崹婊勭椤掍焦鏆柛鎺嶅嵆閳ь剚姘ㄩ悡锟犲触鎼搭垳绀夊ù鍏兼皑閻濇盯宕¢崘鑼闁诡喓鍔庡▓鎴炴媴濠婂啯鎯傚ù鐘插濠€鎵磾閹寸姷褰查柛鎺斿█濞呭酣濡撮敓锟�

   鐎甸偊鍠曟穱濠囧棘閸モ晝褰�  闁稿繗娅曢弫鐐烘儌閻愵剙顎�  閻犲洤瀚鎴﹀礄閻樻彃缍�  闁瑰吋绮庨崒銊╁即閺夋埈妯�